• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » TransEnterix sells 1st ALF-X unit

TransEnterix sells 1st ALF-X unit

August 2, 2016 By Fink Densford

TransEnterixTransEnterix (NYSE:TRXC) said today it sold the 1st ALF-X surgical robotic system to Milan, Italy’s Humanitas Hospital.

The company acquired the Telelap ALF-X robot-assisted surgery device from Italy’s Sofar SpA last September. The Telelap ALF-X device has CE Mark approval in the European Union for minimally invasive surgery procedures.

“We are pleased to announce the first global sale of our ALF-X System. Humanitas is an outstanding academic hospital with a respected multi-specialty surgical program. The ALF-X enables an enhanced surgical program through the use of advanced robotic technology with responsible procedural economics. The initiation of sales of ALF-X represents an important milestone towards realizing our vision to transform surgical robotics. We have made substantial progress building out our global commercial, distribution and service capabilities throughout 2016,” CEO Todd Pope said in a press release.

TransEnterix shelved its SurgiBot robot-assisted surgery device earlier this year after the FDA denied its submission for 510(k) clearance for the SurgiBot, which it claims as the 1st patient-side robotically enhanced laparoscopy platform designed to be wheeled to a patient’s bedside for single-port procedures.

In May, company executives, saying they think getting SurgiBot through the FDA would require another 510(k) submission, said they’re cutting their losses on the project and turning to the ALF-X device. TransEnterix last fall put nearly $100 million on the table for Italy’s Sofar, which developed the Telelap ALF-X and took it through CE Mark approval in the European Union.

TransEnterix CFO Joseph Slattery told analysts during a conference call that the company has already cut $4 million in annual salary costs from the SurgiBot program.

A 510(k) application for the ALF-X device is on track for later this year with FDA clearance hoped for in 2017, Slattery said. CEO Todd Pope said that, notwithstanding the company’s experience with the SurgiBot 510(k), he’s confident in the ALF-X clearance bid.

Filed Under: Business/Financial News, Surgical Robotics Tagged With: TransEnterix

More recent news

  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure
  • NanoVibronix enters into $50M financing agreement

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy